EdgeMarket › What Caligan Partners Lp reported owning
What Caligan Partners Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.5BPositions
28Quarter
2026-03-31Shown below
24largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| LQDA Liquidia Corp | 306.4M | 20.4% | 8.1M | 68.62 | +150.9% |
| ABVX Abivax S.A. | 162.8M | 10.8% | 1.5M | 114.95 | +59.9% |
| RVMD Revolution Medicines, Inc. | 160.7M | 10.7% | 1.7M | 209.46 | +479.3% |
| PCVX Vaxcyte, Inc. | 119.7M | 8.0% | 2.1M | 62.62 | +100.3% |
| XENE Xenon Pharmaceuticals Inc. | 81.0M | 5.4% | 1.4M | 60.77 | +61.5% |
| MLYS Mineralys Therapeutics, Inc. | 75.1M | 5.0% | 2.8M | 25.65 | +65.7% |
| EXEL EXELIXIS, INC. | 66.6M | 4.4% | 1.6M | 54.08 | +42.8% |
| TNGX Tango Therapeutics, Inc. | 50.4M | 3.4% | 2.4M | 23.88 | +253.8% |
| TYRA Tyra Biosciences, Inc. | 48.9M | 3.3% | 1.3M | 26.05 | +154.4% |
| SYRE Spyre Therapeutics, Inc. | 44.3M | 2.9% | 878.1K | 106.49 | +551.3% |
| ADMA ADMA BIOLOGICS, INC. | 42.9M | 2.9% | 4.8M | 9.84 | -43.1% |
| LBRX LB PHARMACEUTICALS INC | 34.6M | 2.3% | 1.4M | 47.62 | — |
| VOR Vor Biopharma Inc. | 34.3M | 2.3% | 1.9M | 23.36 | -46.9% |
| SABS SAB Biotherapeutics, Inc. | 30.5M | 2.0% | 8.0M | 3.78 | +88.1% |
| IRD Opus Genetics, Inc. | 27.6M | 1.8% | 6.1M | 4.05 | +249.1% |
| IVA Inventiva S.A. | 27.6M | 1.8% | 5.0M | 4.68 | +2.2% |
| MBX MBX Biosciences, Inc. | 25.3M | 1.7% | 848.6K | 66.33 | +386.6% |
| AVTX Avalo Therapeutics, Inc. | 24.4M | 1.6% | 1.6M | 19.83 | +115.1% |
| ANIK Anika Therapeutics, Inc. | 20.8M | 1.4% | 1.4M | 21.78 | +160.2% |
| MAZE Maze Therapeutics, Inc. | 18.4M | 1.2% | 615.0K | 29.43 | +118.3% |
| VRCA Verrica Pharmaceuticals Inc. | 4.9M | 0.3% | 923.9K | 4.82 | -13.3% |
| FTH Faeth Therapeutics, Inc. | 4.0M | 0.3% | 126.0K | 32.00 | +302.1% |
| AURA Aura Biosciences, Inc. | 1.5M | 0.1% | 229.9K | 7.80 | +22.4% |
| XLO Xilio Therapeutics, Inc. | 943.0K | 0.1% | 112.1K | 9.23 | -0.6% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →